image description

Tag: Amp

LRA Highlights Groundbreaking Lupus Research at ACR Convergence 2023

This information is brought to you by the Lupus Research Alliance and Lupus Therapeutics and is not sponsored by, nor a part of, the American College of Rheumatology.  30+ presentations of studies funded by the LRA spanning a broad spectrum of research areas Positive results from Phase 2/3 clinical studies supported by LRA affiliate Lupus Therapeutics point to […] Read More

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis

January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […] Read More

LRA Highlights Full Continuum of Lupus Research at ACR Convergence 2020

30+ presentations of studies funded by the Lupus Research Alliance on a variety of immune pathways Results from three clinical studies conducted in part by LRA-affiliate Lupus Therapeutics (LT) through its trials network 10 lupus presentations by the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE) NEW YORK, NY, […] Read More

Good News on Lupus Nephritis Discoveries from ACR Convergence 2020

November 19, 2020 The LRA is proud to share the extraordinary work presented at ACR Convergence 2020 by research members of the Accelerating Medicines Partnership Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) program (AMP RA/SLE).  AMP is a public-private partnership between the National Institutes of Health (NIH), eight biopharmaceutical companies, the LRA and several […] Read More

Accelerating Medicines Partnership Completes Key Phase

September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […] Read More

LRA-Funded Researchers Present Cutting-Edge Science at FOCIS

July 11, 2019 The annual meeting of the Federation of Clinical Immunology Societies (FOCIS) is the key forum for translational immunology. The Lupus Research Alliance (LRA) is proud to co-sponsor this meeting, which allows researchers and clinicians to share knowledge across disease borders and to chart the path to the next major breakthroughs in disease […] Read More

NIH Work Co-Supported by LRA May Simplify Lupus Nephritis Monitoring

June 20, 2019 As reported by the National Institutes of Health (NIH), research published by the NIH Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) “provides new insights into tissue damage for these autoimmune conditions.” AMP RA/SLE is a public-private partnership between the NIH, the pharmaceutical industry and non-profit organizations, including the Lupus […] Read More

Discovering Lupus Heterogeneity

May 22, 2019 Lupus is heterogeneous, meaning that symptoms are many and vary widely from patient to patient — one person may develop a rash, while another may have high blood pressure, joint pain, and anemia. About two thirds of adults with lupus have above-normal levels of immune system molecules called type I interferons that […] Read More

Lupus Research Alliance Congratulates NIH on 5-Year AMP Success

February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery.  In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates